Thelansis

Primary Liver Cancer (PLC) Market Outlook Thelansis’s “Primary Liver Cancer (PLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Liver Cancer (PLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market...

Primary Liver Cancer (PLC) Market Outlook Thelansis’s “Primary Liver Cancer (PLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Liver Cancer (PLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary Liver Cancer (PLC) Overview Primary liver cancer (PLC) is a malignant disease with significant histological and biological diversity. The clinical manifestations of liver cancer are often nonspecific and not evident until cancer has progressed to an advanced stage. These symptoms may comprise unexplained weight loss, loss of appetite, postprandial fullness, nausea, vomiting, abdominal pain or swelling, jaundice (yellow...

 Primary liver cancer (PLC) is a malignant disease with significant histological and biological diversity. The clinical manifestations of liver cancer are often nonspecific and not evident until cancer has progressed to an advanced stage. These symptoms may comprise unexplained weight loss, loss of appetite, postprandial fullness, nausea, vomiting, abdominal pain or swelling, jaundice (yellowing of the skin and sclera), pruritus (itchy skin), and fatigue. Primary liver cancer is mainly divided into hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and HCC-ICC according to pathological type. Each subtype exhibits a distinct genetic makeup and molecular patterns. HCCs are associated with genetic alterations in specific chromosomal regions and genes, including TERT promoter mutation, TP53 deletion, and activation of WNT signaling (CTNNB1 and AXIN1). ICCs exhibit a unique mutational landscape with recurrent mutations, including genetic alterations in TP53, KRAS, is...